Cargando…
Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model
INTRODUCTION: Peritoneal disseminated ovarian cancer is one of the most difficult cancers to treat with conventional anti-cancer drugs and the treatment options are very limited, although an intraperitoneal (ip) paclitaxel has shown some clinical benefit. Therefore, treatment of peritoneal dissemina...
Autores principales: | Iizuka, Kenzo, Jin, Cheng, Eshima, Kokoro, Hong, Mei Hua, Eshima, Kiyoshi, Fukushima, Masakazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881279/ https://www.ncbi.nlm.nih.gov/pubmed/29636601 http://dx.doi.org/10.2147/DDDT.S156635 |
Ejemplares similares
-
A novel intraperitoneal therapy for gastric cancer with DFP‐10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model
por: Ando, Hidenori, et al.
Publicado: (2019) -
Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents
por: Fukushima, Masakazu, et al.
Publicado: (2017) -
Expression of Thymidylate Synthase in Human Non‐small Cell Lung Cancer
por: Otake, Yosuke, et al.
Publicado: (1999) -
Effect of Hammerhead Ribozyme against Human Thymidylate Synthase on the Cytotoxicity of Thymidylate Synthase Inhibitors
por: Kobayashi, Hiroyuki, et al.
Publicado: (1995) -
HCC diagnosis DFP report
Publicado: (2021)